Document is current
Any future updates will be listed below
-
Authors
Xie, Junqing https://orcid.org/0000-0002-0040-0042
Mothe, Beatriz https://orcid.org/0000-0001-9975-407X
Alcalde Herraiz, Marta
Li, Chunxiao
Xu, Yu https://orcid.org/0000-0002-7304-5045
Jödicke, Annika M.
Gao, Yaqing
Wang, Yunhe
Feng, Shuo https://orcid.org/0000-0001-7855-0991
Wei, Jia https://orcid.org/0000-0001-9621-529X
Chen, Zhuoyao https://orcid.org/0000-0003-4201-4649
Hong, Shenda https://orcid.org/0000-0001-7521-5127
Wu, Yeda https://orcid.org/0000-0002-5977-1526
Su, Binbin
Zheng, Xiaoying
Cohet, Catherine https://orcid.org/0000-0002-0022-7251
Ali, Raghib
Wareham, Nick https://orcid.org/0000-0003-1422-2993
Alhambra, Daniel Prieto https://orcid.org/0000-0002-3950-6346
- License Information
-
More Information
Article History
Received: 8 September 2023
Accepted: 29 April 2024
First Online: 13 May 2024
Competing interests
: DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. The remaining authors declare no competing interests.
